TrianglePUBLICATIONS · 15547181
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Natl Cancer Inst
- Publication date
- 2004 Nov 17
- First author
- Vasey PA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Vasey PA
- type
- Author
- name
- Jayson GC
- type
- Author
- name
- Gordon A
- type
- Author
- name
- Gabra H
- type
- Author
- name
- Coleman R
- type
- Author
- name
- Atkinson R
- type
- Author
- name
- Parkin D
- type
- Author
- name
- Paul J
- type
- Author
- name
- Hay A
- type
- Author
- name
- Kaye SB
- type
- Author
- name
- Scottish Gynaecological Cancer Trials Group
- type
- CollectiveName
Complete bibliographic record and source provenance
- authors
- name
- Vasey PA
- type
- Author
- name
- Jayson GC
- type
- Author
- name
- Gordon A
- type
- Author
- name
- Gabra H
- type
- Author
- name
- Coleman R
- type
- Author
- name
- Atkinson R
- type
- Author
- name
- Parkin D
- type
- Author
- name
- Paul J
- type
- Author
- name
- Hay A
- type
- Author
- name
- Kaye SB
- type
- Author
- name
- Scottish Gynaecological Cancer Trials Group
- type
- CollectiveName
- bibliography ids
- nci-bib-fcf91f1a5697af841df782f3
- book metadata
- content sha256
- badd4b661e74f0041c1803dbcd96b850ad47fdc983683179310c240232ed1296
- document type
- citation
- dois
- 10.1093/jnci/djh323
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:15547181
- immutable id
- pubmed:15547181@badd4b661e74f0041c1803dbcd96b850ad47fdc983683179310c240232ed1296
- journal
- abbreviation
- J Natl Cancer Inst
- issn electronic
- 1460-2105
- issn print
- 0027-8874
- issue
- 22
- name
- Journal of the National Cancer Institute
- nlm unique id
- 7503089
- pages
- 1682-91
- volume
- 96
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 15547181
- provenance
- batch id
- 97b9e848a139d5f8d462
- provider
- NCBI PubMed ESummary
- record sha256
- 59cb7e1e743af83c968122352c0d4a206ca651ecd75605ff9b94af82057129d5
- response sha256
- a316b1e9f1b120fc4a41adaaf2b205cc00afcf76d9a093a7cfa9ed2743d05be8
- retrieved at
- 2026-09-09T23:45:57.930512+00:00
- publication date
- display
- 2004 Nov 17
- precision
- day
- year
- 2004
- publication types
- Clinical Trial
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Preserved source evidence · Not medical advice